Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded to 13 directors with immediate appointment of Glenn S. Boehnlein through the 2027 annual meeting.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to 13 directors with immediate appointment of Glenn S. Boehnlein through the 2027 annual meeting
- Independent director adds oversight to Operations & Innovation and Audit committees
- Initial RSU grant valued at $500,000, vesting annually over three years
- Eligible for $347,500 annual RSU grant around the 2027 annual meeting
- Director equity awards fully accelerate upon a Dexcom change in control
Item 7.01 · Regulation FD Disclosure
- Dexcom appointed Mr. Boehnlein to its Board, signaling a governance and strategic leadership change
- Appointment details and rationale are contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Glenn Boehnlein appointed independent director effective September 10, 2026
- Former Stryker CFO brings 20+ years of MedTech finance and operating experience
- Board expertise strengthened in capital allocation, strategic M&A, and global expansion
- Concurrent board roles at Inogen, Agilent Technologies, and Sutter Health indicate extensive governance experience
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.